Momenta biosimilar matches Humira in Phase III trial

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) announced biosimilar candidate M923 showed equivalence to reference product Humira adalimumab, meeting the primary endpoint in a Phase III trial to treat moderate to severe chronic plaque psoriasis. The study measured the primary endpoint by the proportion of patients achieving PASI 75 after 16 weeks of treatment.

M923 also showed equivalence to Humira in secondary endpoints measuring achievement of PASI 50 and PASI 90, proportion of patients achieving clear or near-clear skin, and absolute PASI score. Patients received either of the two versions of adalimumab, or Humira alternating with M923, for up to 48 weeks...